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Although leaded gasoline has been phased out
for decades, lead continues to be a public
health concern. Lead accumulates in the
human body and has been linked to increased
cancer and cardiovascular mortality (Lustberg
and Silbergeld 2002). Most studies of the
cardiovascular effects of lead in humans have
focused on lead’s causal relationship with
hypertension. Although the results are con-
troversial, a meta-analysis has revealed a weak
but signiﬁcantly positive association between
blood lead level and blood pressure (Nawrot
et al. 2002). Meanwhile, an association
between lead exposure and serum cholesterol
and lipoprotein levels was found in workers
of battery and recycling factories (el-Gazzar
et al. 1989; Kristal-Boneh et al. 1999), indi-
cating a risk for the development of athero-
sclerosis. Studies in animals also suggested
that lead exposure may promote athero-
sclerosis, as shown by fatty degeneration and
sclerotic changes on artery walls of lead-
intoxicated rats (Skoczynska et al. 1993). A
recent study in the general U.S. population has
shown an association of blood lead with ele-
vated prevalence of peripheral arterial disease, a
disorder characterized by atherosclerosis in the
arteries of the lower extremities (Navas-Acien
et al. 2004).
Human paraoxonase 1 (PON1) is a serum
esterase transported on high-density lipo-
protein (HDL) particles. PON1 is thought to
attenuate the oxidation of low-density
lipoprotein (LDL) and therefore protect
against the development of atherosclerosis,
although the exact mechanisms and substrates
for PON1 are unclear. Animal studies have
strongly supported the protective role of
PON1 in atherosclerosis. PON1-knockout
mice were prone to develop atherosclerotic
plaques when fed a high-fat diet (Shih et al.
1998), and these animals had increased oxida-
tive stress in both serum and macrophages
(Rozenberg et al. 2003). On the other hand,
PON1-overexpressing mice showed a reduc-
tion in atherosclerotic lesion formation (Tward
et al. 2002), and their HDL was more resistant
to oxidative damage (Oda et al. 2002). The
role of PON1 in cardiovascular disease has also
been suggested by epidemiologic studies. A
coding region polymorphism (Q192R) of the
human PON1 gene (Wheeler et al. 2004) and
low serum PON1 activity levels (Jarvik et al.
2000; Mackness et al. 2001, 2003) were both
associated with increased incidence of coronary
heart disease.
The enzymatic activity of PON1 is mainly
determined by the Q192R polymorphism
(Humbert et al. 1993). However, a variety of
environmental and pharmaceutical factors are
able to modulate PON1 activity as well.
Previous studies have shown that various met-
als, including lead at concentrations < 1 µM,
caused signiﬁcant inhibition of PON1 activity
in vitro (Cole et al. 2002; Debord et al. 2003).
Whether long-term, low-level lead exposure
has any effect on PON1 activity in vivo is yet
to be investigated.
The aim of the present study was to under-
stand whether lead exposure has any effects on
serum PON1 activity and serum cholesterol
levels. We conducted a cross-sectional study
to evaluate the relationship between blood
lead level, serum cholesterol and lipoprotein
levels, and serum PON1 activity in a cohort
of workers of lead-acid battery and recycling
plants. Results of this study may help us
understand the possible interaction between
lead and polymorphisms of genes that encode
proteins known to be involved in regulation
of atherosclerosis.
Materials and Methods
Study population. We carried out this study
in a lead-acid battery manufactory and a lead
recycling plant, where workers have been fol-
lowed since 1990 with annual health exami-
nations, including physical examination,
blood lead test, hematology test, serum lipids
test, and liver and renal function tests. A
total of 597 workers 21–61 years of age
(mean ± SD, 40.2 ± 15.3 years) were
enrolled in this study. We collected blood
samples on-site during the annual health
examination in 2002. Buffy coat isolated
from EDTA-treated blood was used for
genomic DNA preparation, whereas serum
was collected for the PON1 activity assay. All
samples were stored at –20°C until measure-
ment. This protocol was approved by the
institutional review board of Kaohsiung
Medical University, and informed consent
was obtained from subjects before the study.
Chemicals and materials. Phenyl acetate
(purity 99%) was purchased from Sigma-
Aldrich (St. Louis, MO, USA), and paraoxon
(purity 98.5%) and diazinon-oxon (purity
97.4%) were obtained from Chem Service
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Lead exposure causes cardiac and vascular damage in experimental animals. However, there is con-
siderable debate regarding the causal relationship between lead exposure and cardiovascular dys-
function in humans. Paraoxonase 1 (PON1), a high-density lipoprotein-associated antioxidant
enzyme, is capable of hydrolyzing oxidized lipids and thus protects against atherosclerosis. Previous
studies have shown that lead and several other metal ions are able to inhibit PON1 activity
in vitro. To investigate whether lead exposure has influence on serum PON1 activity, we con-
ducted a cross-sectional study of workers from a lead battery manufactory and lead recycling plant.
Blood samples were analyzed for whole-blood lead levels, serum PON1 activity, and three com-
mon PON1 polymorphisms (Q192R, L55M, –108C/T). The mean blood lead level (± SD) of this
cohort was 27.1 ± 15 µg/dL. Multiple linear regression analysis showed that blood lead levels were
significantly associated with decreased serum PON1 activity (p < 0.001) in lead workers. This
negative correlation was more evident for workers who carry the R192 allele, which has been sug-
gested to be a risk factor for coronary heart disease. Taken together, our results suggest that the
decrease in serum PON1 activity due to lead exposure may render individuals more susceptible to
atherosclerosis, particularly subjects who are homozygous for the R192 allele. Key words: athero-
sclerosis, lead, metal, paraoxonase, polymorphism. Environ Health Perspect 114:1233–1236
(2006). doi:10.1289/ehp.9163 available via http://dx.doi.org/ [Online 18 May 2006](West Chester, PA, USA). Ultraviolet-
transparent 96-well plates were purchased
from Costar (Cambridge, MA, USA), and
standard 96-well plates were from Nunc
(Roskilde, Denmark).
Blood lead level measurement. Blood lead
levels were analyzed by a Zeeman effect
graphite furnace atomic absorption spectrom-
eter (PerkinElmer 5100 PC with AS 60 auto-
sampler; PerkinElmer, Wellesley, MA, USA).
PON1 activity assay. PON1 arylesterase
activity was measured in 9 mM Tris-HCl,
pH 8, and 0.9 mM calcium chloride with
3.26 mM phenyl acetate at 27°C (Furlong
et al. 1988). The rate of phenol generation
was monitored at 270 nM, and a molar
extinction coefﬁcient of 1,310 was used to cal-
culate the enzyme activity. PON1 paraoxonase
activity was measured using 1.2 mM paraoxon
in 0.1 M Tris-HCl, pH 8.5, 2 mM CaCl2,
and 2 M NaCl at 37°C (Furlong et al. 1988).
Reaction was monitored at 405 nM, and an
extinction coefficient of 18 mM–1cm–1 was
used for activity calculation. PON1 activity
for hydrolyzing diazoxon was determined as
previously described (Furlong et al. 1989;
Richter and Furlong 1999), with minor modi-
ﬁcation. PON1 diazoxonase activity was mea-
sured using 1 mM diazoxon in 0.1 M
Tris-HCl, pH 8.5, 2 mM CaCl2, and 2.5 M
NaCl at 27°C. Reaction was monitored at
270 nM, and an extinction coefficient of
3m M –1cm–1 was used for calculation. PON1
activity was expressed as micromoles of
hydrolysis product formed per minute per
liter or milliliter. The assays were performed
in a 96-well microplate spectrophotometer
SPECTRAMax 190 (Molecular Devices,
Sunnyvale, CA, USA).
PON1 genotyping. Genomic DNA was
extracted from buffy coat using a commercial
kit (QIAamp DNA Mini Kit; Qiagen, Hilden,
Germany). All genotyping was conducted by
polymerase chain reaction amplification fol-
lowed by polymorphism-specific restriction
enzyme digestion and gel analysis. The Q192R
and L55M polymorphisms were determined
following a protocol developed by Humbert
et al. (1993), whereas the promoter region
polymorphism –108C/T was determined
according to Brophy et al. (2001).
Statistical analysis. Differences between
groups were analyzed using one-way analysis
of variance (ANOVA). The magnitude of the
correlation between PON1 activity, blood
lead level, and serum lipids was assessed by
Pearson coefficient of correlation. Deviation
from Hardy-Weinberg equilibrium was evalu-
ated using chi-square tests. Multiple linear
regression analysis, controlling for PON1
genotypes and potential confounding factors,
was used to test the association between
PON1 activities, or serum lipids, and blood
lead level.
Results
A total of 597 workers were evaluated for their
blood lead levels, serum lipids, and PON1
activities. The mean (± SD) blood lead level of
this cohort was 27.1 ± 15 µg/dL. Workers were
divided into low (≤ 10 µg/dL), medium
(10–40 µg/dL), and high (> 40 µg/dL) expo-
sure groups based on their blood lead levels
(Table 1), where 10 µg/dL is the criterion for
elevated blood levels in children and pregnant
women set by the U.S. Centers for Disease
Control and Prevention (CDC 2005) and
40 µg/dL is the highest level accepted by the
standards of the U.S. Occupational Safety and
Health Administration (OSHA 2003) and the
Taiwan government (Institute of Occupational
Safety and Health 2002). The high-exposure
group included mostly males with the longest
work history and the highest smoking rate. No
difference was found in systolic or diastolic
blood pressure. Only triglyceride level was dif-
ferent among the three groups, with the
medium-exposure group having the highest
level of triglycerides. Multiple linear regression
analysis revealed that, after controlling for age,
sex, work history, smoking, and body mass
index (BMI), blood lead was negatively associ-
ated with triglycerides but positively associated
with HDL cholesterol (Table 2).
Interestingly, we found signiﬁcant differ-
ences in serum PON1 activities among the
three exposure groups (Table 1). We deter-
mined PON1 activities using three different
substrates, phenyl acetate (arylesterase),
paraoxon, and diazoxon, and all three activi-
ties were decreased with increasing exposure
level. The average paraoxonase activity of the
high-exposure group was approximately 18%
lower than the low-exposure group (714.4 ±
343.5 vs. 869.2 ± 399.9 µmol/min/L).
We determined three common polymor-
phisms of the human PON1 gene, and the
gene frequencies of Q192R, L55M, and
–108C/T were similar to those reported in
the literature for the Chinese population
(Wang et al. 2003) (Table 3). As expected,
paraoxonase and diazoxonase activities were
inﬂuenced by the Q192R and –108C/T poly-
morphisms. Our data showed that arylesterase
activity was also affected by the Q192R poly-
morphism, which is in contrast to the general
belief that arylesterase activity is independent
of the polymorphism at position 192.
Table 4 represents a multivariate linear
regression model for serum PON1 activities.
PON1 polymorphisms, blood lead, HDL cho-
lesterol, sex, smoking, age, and work history
were included in the model. Collectively, these
variables were associated with 35.3% of vari-
ance in arylesterase and paraoxonase activities
and 64.9% of variance in diazoxonase activity.
Blood lead was found to be an independent
Li et al.
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Table 1. Demographic characteristics of lead workers in Taiwan.
BPb (µg/dL)
Characteristic Low (BPb ≤ 10) Medium (10 < BPb ≤ 40) High (BPb > 40)
No. 85 384 128
Age (year) 37.5 ± 8.5 39.7 ± 8.7* 40.7 ± 8.3*
Sex (% male) 65.9 72.7* 85.2*
Smoking (%) 16.5 37.4* 50.0*
Years working 9.1 ± 6.9 10.7 ± 5.8* 10.9 ± 5.4*
BMI (kg/m2) 23.3 ± 3.5 24.5 ± 3.7* 23.9 ± 3.8
SBP (mmHg) 126.5 ± 12.7 127.3 ± 13.7 128.2 ± 14.7
DBP (mmHg) 77.5 ± 8.9 78.5 ± 10.4 76.7 ± 10.9
Triglycerides (mg/dL) 125.9 ± 76.9 151.6 ± 131.3* 124.0 ± 73.8
Total cholesterol (mg/dL) 187.1 ± 29.3 195.3 ± 34.6 191.7 ± 37.5
HDL (mg/dL) 49.0 ± 12.1 48.8 ± 11.6 49.1 ± 10.7
Arylesterase (µmol/min/mL) 103.9 ± 33.5 93.6 ± 32.3* 90.9 ± 35.8*
Paraoxonase (µmol/min/L) 869.2 ± 399.9 826.8 ± 394.1* 714.4 ± 343.5*
Diazoxonase (µmol/min/L) 7,001 ± 3,894 6,341 ± 3,581 6,164 ± 3,677
Abbreviations: BPb, blood lead level; DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are mean ± SD. 
*p < 0.05 by one-way ANOVA or chi-square test. 
Table 2. Multiple linear regression analysis for association of blood lead level with serum lipids.
HDL cholesterol Triglyceridesa Total cholesterol
Variable β (SE) p-Value β (SE) p-Value β (SE) p-Value
Blood lead 0.066 (0.033) 0.043 –0.0014 (0.001) 0.041 –0.122 (0.104) 0.238
Arylesterase 0.053 (0.014) 0.000 –0.00003 (0.000) 0.912 0.0651 (0.044) 0.138
Sex –7.367 (1.157) 0.000 0.0617 (0.024) 0.011 –0.903 (3.659) 0.805
Smoking –1.952 (1.106) 0.078 0.0582 (0.023) 0.012 –4.362 (3.496) 0.213
Age 0.00071 (0.055) 0.990 0.0015 (0.001) 0.187 0.570 (0.175) 0.001
Work historyb –5.625 (3.902) 0.150 0.107 (0.081) 0.189 2.849 (12.3) 0.818
BMI –0.749 (0.124) 0.000 0.0254 (0.003) 0.000 2.317 (0.393) 0.000
Intercept 67.960 (3.838) 0.000 1.335 (0.080) 0.000 112.188 (12.1) 0.000
R2 0.217 0.225 0.102
aTriglycerides values were log-transformed to improve normality. bWork history represents the ratio of work years to age.factor affecting serum PON1 activity. An
increase of 1 µg/dL in blood lead would result
in a decrease of 0.403 µmol/min/mL in
arylesterase activity, 4.059 µmol/min/L in
paraoxonase activity, and 29.244 µmol/min/L
in diazoxonase activity. When subjects were
separated by their Q192R genotype (Figure 1),
the negative correlation between blood lead and
paraoxonase activity was signiﬁcant only in sub-
jects of RR genotype (r = –0.251, p < 0.001),
but not in subjects of QR (r = –0.101,
p = 0.122) or QQ genotype (r = –0.007,
p = 0.959). This result indicates significant
effects on serum paraoxonase activity by inter-
action between blood lead and the Q192R
polymorphism.
Discussion
The main ﬁnding of the present study is that
lead exposure is associated with decreased
serum PON1 activity. The reverse dose–
response relationship between blood lead and
PON1 activity was demonstrated in a large
cohort of active lead workers (n = 597).
Moreover, our study is the first report in
humans showing an inhibitory effect of heavy
metal exposure on PON1 activity. This is
consistent with the results of previous in vitro
studies in which various metals, including
lead, have been shown to inhibit the activity
of purified human PON1 (Debord et al.
2003). In the study by Cole et al. (2002), lead
chloride at < 1 µM was able to inhibit the
arylesterase activity of puriﬁed human PON1
by > 50%. The average blood lead of our
cohort was 27 µg/dL, equal to 1.3 µM, which
is comparable to the doses tested by Cole
et al. (2002). This indicates that our ﬁnding is
biologically plausible, rather than merely a
statistical coincidence.
Our results also show a weak effect of lead
exposure on serum lipids, where a negative
association was found between blood lead and
triglycerides, and a positive association was
found for HDL cholesterol. It agrees with a
previous report in which HDL cholesterol was
higher among lead workers than in controls
(Kristal-Boneh et al. 1999). Although increased
HDL cholesterol and low triglyceride levels
could be argued to be a “protective effect,” we
found that it may not be the case. First, the
effect of lead exposure on serum lipids was very
weak (β = 0.066 for HDL; β = –0.001 for log
triglycerides) with marginal significance
(p = 0.043 for HDL; p = 0.041 for log tri-
glycerides) (Table 2). It is unlikely that this
effect on serum lipids would result in any
beneficial outcome. Second, the antioxidant
function of HDL particles is mainly attributed
to PON1. Because PON1 activity is decreased,
the protective effect of HDL is likely to be
damaged, as well. Therefore, even though
HDL cholesterol is slightly increased with
blood lead level, its protection against athero-
sclerosis may not be increased.
The mechanism by which heavy metals
inhibit serum PON1 activity is still not clear.
Gonzalvo et al. (1997) suggested that metal
ions, such as copper and mercury, bind to the
free sulfhydryl group of the enzyme. PON1
has three cysteine residues; two of them form a
disulﬁde bond, and the third one—located at
residue 284—is free. Although this residue
(Cys284) is not at the active site for hydrolytic
activity of PON1, its mutation or blockage is
likely to destabilize the structure of PON1 and
affect its function (Harel et al. 2004). More
important, this free sulfhydryl group is
required for protection of PON1 against LDL
Pb is associated with decreased serum PON1 activity
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Table 3. Serum PON1 activities and PON1 genotypes in lead workers. 
Arylesterase Paraoxonase Diazoxonase
PON1 genotype (µmol/min/mL) (µmol/min/L) (µmol/min/L)
Q192R
QQ (n = 61) 124.5 ± 30.9 382.9 ± 130.5 11,113 ± 2,797
QR (n = 256) 102.6 ± 30.0 723.3 ± 294.2 7,893 ± 2,768
RR (n = 210) 76.5 ± 27.5 1035.5 ± 391.3 3,223 ± 1,594
p-Value < 0.001 < 0.001 < 0.001
–108C/T
CC (n = 154) 112.0 ± 33.8 696.7 ± 379.4 8,693 ± 3,560
CT (n = 265) 93.0 ± 30.4 826.3 ± 396.0 6,206 ± 3,334
TT (n = 108) 74.2 ± 26.0 935.4 ± 335.2 3,629 ± 2,113
p-Value < 0.001 < 0.001 < 0.001
L55M
LL (n = 497) 95.3 ± 33.5 831.2 ± 387.0 6,438 ± 3,698
LM (n = 30) 84.5 ± 28.1 507.1 ± 251.6 5,856 ± 2,666
p-Value < 0.001 < 0.001 < 0.001
Allele frequencies for polymorphisms are as follows: Q192R, Q = 0.359, R = 0.641; –108C/T, C = 0.544, T = 0.456; and L55M,
L = 0.972, M = 0.028. No individuals were homozygous for the M allele in this cohort. Data are mean ± SD. Statistical signiﬁ-
cance between genotypes was analyzed by one-way ANOVA and Scheffe test.
Table 4. Multivariate regression model for associations with serum arylesterase, paraoxonase and diazox-
onase activities.
Arylesterase Paraoxonase Diazoxonase
β SE p-Value β SE p-Value β SE p-Value
Q192R
QR vs. RR 21.611 2.923 < 0.001 –346.633 35.251 < 0.001 4489.059 754.545 < 0.001
QQ vs. RR 41.627 4.671 < 0.001 –686.910 57.074 < 0.001 7585.392 376.229 < 0.001
–108C/T
CT vs. CC –9.854 3.077 0.001 –54.361 37.322 0.146 –762.829 247.806 0.002
TT vs. CC –19.713 4.418 < 0.001 –124.209 50.611 0.014 –1366.551 334.128 < 0.001
55L/M
LM vs. LL –25.393 5.331 < 0.001 –150.240 62.424 0.016 –3062.718 429.351 < 0.001
Blood lead –0.403 0.086 < 0.001 –4.059 1.026 < 0.001 –29.244 6.932 < 0.001
HDL cholesterol 0.411 0.113 < 0.001 3.514 1.348 0.009 20.441 9.086 0.025
Sex 2.211 3.179 0.487 30.724 38.245 0.422 –13.215 256.047 0.959
Smoking 3.336 2.922 0.254 7.450 35.265 0.833 167.126 235.341 0.478
Age –0.090 0.145 0.535 1.243 1.758 0.480 –11.638 11.662 0.319
Work history –14.209 10.288 0.168 –223.850 122.519 0.068 –1402.009 828.617 0.091
Intercept 84.146 9.368 < 0.001 1031.287 113.345 < 0.001 4683.922 754.545 < 0.001
R2 0.353 0.353 0.649
Figure 1. Linear regression trend between blood
lead level and serum paraoxonase activity among
lead workers in Taiwan shown by PON1 Q192R
genotype. (A) RR homozygotes (r = –0.251, p < 0.001).
(B) QR heterozygotes (r = –0.101, p < 0.122). (C)Q Q
homozygotes (r = –0.007, p < 0.959).
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oxidation (Aviram et al. 1998). If lead, acting
like other divalent metal ions, binds to the free
sulfhydryl group of PON1, it will reduce not
only the hydrolytic activity of PON1 but also
its antioxidant function.
Lead is well known to cause cardiovascular
damage, including atherosclerosis. PON1
plays an important role in protection against
this disease by removing LDL peroxides,
whose accumulation is a critical step in the
development of atherosclerosis. It seems rea-
sonable to assume that the decreased PON1
activity found among lead workers also repre-
sents a reduced protection against LDL oxida-
tion, thereby increasing the accumulation of
lipid peroxides and, eventually, promoting
atherosclerosis. The relationship between
blood lead and other antioxidant enzymes has
been reported previously by Ito et al. (1985),
who found that occupational lead exposure
was associated with decreased superoxide dis-
mutase activity while the levels of serum lipid
peroxides were increased. Our data provide
further evidence that lead exposure may
increase oxidative stress by inhibiting anti-
oxidant enzymes.
Interestingly, the inhibitory effect of lead
on PON1 activity is inﬂuenced by the Q192R
polymorphism. The present study indicates
that, in terms of paraoxonase activity, subjects
who are homozygous for the R allele are more
susceptible to lead toxicity than are subjects of
other genotypes (Figure 1). The lower stability
of the R allele compared to the Q allele was
also observed in an oxidizing environment.
The HDL isolated from the RR subjects
retained < 1% of antioxidant function after
6 hr of incubation, whereas the QQ HDL
kept > 50% of its original activity (Mackness
et al. 1998). On the other hand, the R allele
was also more sensitive to the beneﬁcial effects
of environmental factors, because the effects of
an antiatherogenic diet (Bub et al. 2002;
Tomas et al. 2001) or physical activity (Senti
et al. 2000) were found only in subjects carry-
ing the R allele. Together with our data, all
the findings suggest a significant interaction
between the Q192R polymorphism and
environmental factors. This implies that the
effect of the Q192R polymorphism on a par-
ticular trait, such as cardiovascular disease,
may be enhanced or diluted by certain
environmental factors.
In summary, lead exposure is associated
with decreased serum PON1 activity, and this
inhibitory effect is most obvious for subjects
who carry two R alleles. Whether this event
leads to more profound cardiovascular dam-
age in lead workers is yet to be explored.
However, because of the protective role of
PON1 in the development of atherosclerosis,
serum PON1 activity could be used as a bio-
marker to monitor the cardiovascular health
among lead workers.
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